Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.
Earnings & Valuation
This table compares Finch Therapeutics Group and Cardiff Oncology’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Finch Therapeutics Group | $110,000.00 | 33.66 | -$74.75 million | ($47.67) | -0.05 |
| Cardiff Oncology | $488,000.00 | 322.50 | -$41.44 million | ($0.90) | -3.91 |
Cardiff Oncology has higher revenue and earnings than Finch Therapeutics Group. Cardiff Oncology is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Finch Therapeutics Group | 0 | 0 | 0 | 0 | N/A |
| Cardiff Oncology | 0 | 0 | 2 | 0 | 3.00 |
Cardiff Oncology has a consensus target price of $10.50, suggesting a potential upside of 198.30%. Given Cardiff Oncology’s higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Finch Therapeutics Group.
Volatility & Risk
Finch Therapeutics Group has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.
Profitability
This table compares Finch Therapeutics Group and Cardiff Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Finch Therapeutics Group | N/A | -136.63% | -57.40% |
| Cardiff Oncology | -6,594.92% | -51.54% | -45.11% |
Insider and Institutional Ownership
21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 6.3% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Cardiff Oncology beats Finch Therapeutics Group on 9 of the 13 factors compared between the two stocks.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
